drugset / Trial / NCT01483144

Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)

NCT01483144

Phase 3 Completed 171 enrolled Cancer Prevention Pharmaceuticals, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this randomized, double-blind, Phase III trial is to determine if the combination of eflornithine plus sulindac is superior to sulindac or eflornithine as single agents in delaying time to the first occurrence of any FAP-related event. This includes: 1) FAP related disease progression indicating the need for excisional intervention involving the colon, rectum, pouch, duodenum and/or 2) clinically important events which includes progression to more advanced duodenal polyposis, cancer or death.

Timeline

Start
2013-10
Primary completion
2018-11
Completion
2019-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Eflornithine Small molecule 750 mg Oral
Subject Sulindac 150 MG Unknown 150 mg Oral